China NMPA Drug Inspection - Gansu Sanlong Ankang Pharmaceutical Co., Ltd.

In an announcement released on December 21, 2020, the Gansu Provincial Drug Administration reported that 11 batches of pharmaceutical products failed to meet national quality standards during recent sampling inspections. The testing, conducted by the Gannan Tibetan Autonomous Prefecture Drug Inspection and Testing Center and other regional institutions, identified ten non-compliant companies, specifically highlighting Gansu Sanlong Ankang Pharmaceutical Co., Ltd. Under the regulatory oversight of the National Medical Products Administration (NMPA), local market supervision departments have taken immediate action to seal and seize the substandard products. Formal investigations into the manufacturers are currently underway to address the compliance failures. The regulatory framework requires these companies to perform root cause analyses, implement corrective measures, and eliminate potential public health risks. Local bureaus have been directed to intensify their supervision of these entities, with the final results of the investigations and enforcement actions expected to be made public within three months. This action aims to maintain the integrity of the pharmaceutical supply chain and ensure all medications meet safety and efficacy requirements.